MARKET

ATNX

ATNX

Athenex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.39
+0.58
+4.91%
After Hours: 12.39 0 0.00% 16:12 09/25 EDT
OPEN
12.16
PREV CLOSE
11.81
HIGH
12.48
LOW
12.00
VOLUME
716.41K
TURNOVER
--
52 WEEK HIGH
18.35
52 WEEK LOW
5.63
MARKET CAP
1.14B
P/E (TTM)
-8.4840
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
FDA OKs Athenex IND application for TCRT-ESO-A2
Athenex (ATNX) announced that the USFDA has allowed its investigational new drug application for TCRT-ESO-A2, an autologous T cell receptor ((TCR))-T cell therapy targeting solid tumors that are NY-ESO-1 positive
Seekingalpha · 2d ago
Athenex Announces FDA Allowance Of IND Application For TCRT-ESO-A2, A TCR-T Cell Therapy
BUFFALO, N.Y., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of
Benzinga · 2d ago
Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy
Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S.BUFFALO, N.Y., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies
GlobeNewswire · 2d ago
A Biotech Pro Bought Up These 3 Stocks
Barrons.com · 6d ago
Athenex (ATNX) Investor Presentation - Slideshow
The following slide deck was published by Athenex, Inc. in conjunction with this event.
Seekingalpha · 09/11 21:42
Agenus, Achieve Life Sciences leads gainers, Satsuma Pharmaceuticals, Precipio among losers
Gainers:  Agenus (AGEN) +13%, Achieve Life Sciences (ACHV) +7%, Agile Therapeutics (AGRX) +7%, Akouos (AKUS) +7%, Adial Pharmaceuticals (ADIL) +6%.Losers: Satsuma Pharmaceuticals (STSA) -75%, Precipio (PRPO) -22%, Sutro Biopharma (STRO) -18%, Athenex (ATNX) -16%, Spero Therapeutics (SPRO) -15%.
Seekingalpha · 09/10 15:10
TRQ, CSIQ among premarket losers
Turquoise Hill Resources (TRQ) -21% after announcing an update on funding discussions with Rio Tinto.Precipio (PRPO) -17%.Muscle Maker (GRIL) -14%.GameStop (GME) -10% after Q2 earnings fall short of expectations.Athenex (ATNX) -8% after pricing stock offering.FuelCell Energy
Seekingalpha · 09/10 12:18
Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
BUFFALO, N.Y., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing of a public offering of 10,000,000 shares of its
GlobeNewswire · 09/10 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNX. Analyze the recent business situations of Athenex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATNX stock price target is 28.24 with a high estimate of 38.00 and a low estimate of 16.67.
EPS
Institutional Holdings
Institutions: 146
Institutional Holdings: 48.22M
% Owned: 52.59%
Shares Outstanding: 91.69M
TypeInstitutionsShares
Increased
31
1.84M
New
37
-292.49K
Decreased
38
2.16M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.00%
Pharmaceuticals & Medical Research
+1.53%
Key Executives
Chairman/Chief Executive Officer/Director
Johnson Lau
Chief Financial Officer
Randoll Sze
Corporate Executive
William Zuo
Chief Operating Officer
Jeffrey Yordon
Senior Director
Daniel Lang
Other
Rudolf Kwan
Other
Simon Pedder
Lead Director/Independent Director
Kim Campbell
Director
Manson Fok
Director
Robert Spiegel
Independent Director
Stephanie Davis
Independent Director
Jordan Kanfer
Independent Director
Tiong Lu Koh
Independent Director
Kwan Hung Tsang
Independent Director
Benson Tsang
Independent Director
John Vierling
Independent Director
Jinn Wu
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATNX
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Athenex Inc stock information, including NASDAQ:ATNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNX stock methods without spending real money on the virtual paper trading platform.